The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
Document Type
Journal Article
Publication Date
4-25-2020
Journal
Journal of the American Academy of Dermatology
DOI
10.1016/j.jaad.2020.04.104
APA Citation
Simpson, E., Bissonnette, R., Eichenfield, L. F., Guttman, E., King, B., Silverberg, J. I., Beck, L. A., Bieber, T., Reich, K., Kabashima, K., Seyger, M., Siegfried, E., Stingl, G., Feldman, S. R., Menter, A., van de Kerkhof, P., Yosipovitch, G., Paul, C., Martel, P., Dubost-Brama, A., Armstrong, J., Chavda, R., Frey, S., Joubert, Y., Milutinovic, M., Parneix, A., Teixeira, H. D., Lin, C., Sun, L., Klekotka, P., Nickoloff, B., Dutronc, Y., Mallbris, L., Janes, J. M., DeLozier, A. M., Nunes, F., & Paller, A. S. (2020). The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.. Journal of the American Academy of Dermatology, (). http://dx.doi.org/10.1016/j.jaad.2020.04.104
Peer Reviewed
1
Comments
Online ahead of print